GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » PB Ratio

Five Prime Therapeutics (Five Prime Therapeutics) PB Ratio : 6.57 (As of May. 12, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Five Prime Therapeutics's share price is $38.00. Five Prime Therapeutics's Book Value per Share for the quarter that ended in Dec. 2020 was $5.78. Hence, Five Prime Therapeutics's PB Ratio of today is 6.57.

The historical rank and industry rank for Five Prime Therapeutics's PB Ratio or its related term are showing as below:

FPRX' s PB Ratio Range Over the Past 10 Years
Min: 0.56   Med: 2.57   Max: 8.82
Current: 6.61

During the past 11 years, Five Prime Therapeutics's highest PB Ratio was 8.82. The lowest was 0.56. And the median was 2.57.

FPRX's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs FPRX: 6.61

During the past 12 months, Five Prime Therapeutics's average Book Value Per Share Growth Rate was 23.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -15.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -24.30% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Five Prime Therapeutics was 75.10% per year. The lowest was -34.20% per year. And the median was -15.80% per year.

Back to Basics: PB Ratio


Five Prime Therapeutics PB Ratio Historical Data

The historical data trend for Five Prime Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Five Prime Therapeutics PB Ratio Chart

Five Prime Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.52 2.33 1.22 1.07 2.94

Five Prime Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.60 1.80 1.76 2.94

Competitive Comparison of Five Prime Therapeutics's PB Ratio

For the Biotechnology subindustry, Five Prime Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Five Prime Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's PB Ratio falls into.



Five Prime Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Five Prime Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2020)
=38.00/5.782
=6.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Five Prime Therapeutics  (NAS:FPRX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Five Prime Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Executives
William R Ringo director
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White officer: See Remarks 4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins officer: EVP and Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451

Five Prime Therapeutics (Five Prime Therapeutics) Headlines